GH001
Phase 2Terminated 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Postpartum Depression
Conditions
Postpartum Depression, Postnatal Depression
Trial Timeline
Mar 2, 2023 → Nov 15, 2024
NCT ID
NCT05804708About GH001
GH001 is a phase 2 stage product being developed by GH Research for Postpartum Depression. The current trial status is terminated. This product is registered under clinical trial identifier NCT05804708. Target conditions include Postpartum Depression, Postnatal Depression.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05839509 | Phase 2 | Terminated |
| NCT05804708 | Phase 2 | Terminated |
Competing Products
20 competing products in Postpartum Depression
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Misoprostol + Oxytocin | Cipla | Phase 3 | 77 |
| Quetiapine | AstraZeneca | Phase 2 | 52 |
| Azithromycin + Azithromycin and amoxicillin + Placebo | Merck | Approved | 85 |
| Eptacog alfa (NovoSeven) | Novo Nordisk | Approved | 84 |
| Eptacog alfa (activated) | Novo Nordisk | Pre-clinical | 22 |
| aripiprazole | Bristol Myers Squibb | Phase 3 | 76 |
| fibrinogen concentrate + Placebo | CSL | Phase 1/2 | 40 |
| SAGE-217 15/20 mg Oral Solution + Placebo + SAGE 217 30 mg Capsules | Biogen | Phase 3 | 74 |
| SAGE-217 + Placebo | Biogen | Phase 3 | 74 |
| Zuranolone | Biogen | Pre-clinical | 20 |
| Zuranolone | Biogen | Pre-clinical | 20 |
| LPCN 1154A + Placebo | Lipocine | Phase 3 | 69 |
| Goserelin 3.6 mg implant + Placebo | Brain Biotech | Pre-clinical | 15 |
| ZULRESSO (brexanolone) injection | Supernus Pharmaceuticals | Pre-clinical | 18 |
| Placebo + SAGE-547 90 μg/kg/h | Supernus Pharmaceuticals | Phase 3 | 72 |
| ZULRESSO® | Supernus Pharmaceuticals | Approved | 80 |
| SAGE-547 | Supernus Pharmaceuticals | Phase 2 | 47 |
| Placebo + SAGE-547 60 μg/kg/h + SAGE-547 90 μg/kg/h | Supernus Pharmaceuticals | Phase 3 | 72 |
| SAGE-547 + Placebo | Supernus Pharmaceuticals | Phase 2 | 47 |
| Brexanolone | Brain Biotech | Pre-clinical | 15 |